OncoMatch/Clinical Trials/NCT05132504
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Is NCT05132504 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Folfirinox for pancreatic ductal adenocarcinoma.
Treatment: Pembrolizumab · Folfirinox — Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoadjuvant Trial Type: Interventional prospective Type of control: Historical Route of administration: IV Treatment Groups: Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Number of trial participants: 30 Estimated enrollment period: 24 months Estimated duration of trial: 3.5 Years Duration of Participation:16 months Estimated average length of treatment per patient: 16 months
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage LOCALIZED, POTENTIALLY RESECTABLE
Excluded: Stage BORDERLINE RESECTABLE, III, ADVANCED METASTATIC
localized adenocarcinoma of the pancreas that is potentially resectable
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Patient must not have received prior chemotherapy or radiation for pancreatic cancer.
Cannot have received: radiation therapy
Patient must not have received prior chemotherapy or radiation for pancreatic cancer.
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1500/μl; platelets ≥100 000/μl; hemoglobin ≥9.0 g/dl or ≥5.6 mmol/l
Kidney function
creatinine ≤1.5 × uln or ≥30 ml/min for participant with creatinine levels >1.5 × institutional uln
Liver function
total bilirubin ≤1.5 ×uln or direct bilirubin ≤uln for participants with total bilirubin levels >1.5 × uln; ast (sgot) and alt (sgpt) ≤2.5 × uln (≤5 × uln for participants with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Baylor College of Medicine · Houston, Texas
- Baylor St. Luke's Medical Center (BSLMC). · Houston, Texas
- Houston Methodist Hospital · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05132504 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage LOCALIZED or POTENTIALLY RESECTABLE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages